{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:38:16Z","timestamp":1786621096090,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40257-026-01043-0","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T08:47:04Z","timestamp":1779871624000},"page":"841-849","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study"],"prefix":"10.1007","volume":"27","clinical-trial-number":[{"clinical-trial-number":"nct05456529","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7300-8516","authenticated-orcid":false,"given":"Joel C.","family":"Joyce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9963-8319","authenticated-orcid":false,"given":"H. Chih-ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dareen D.","family":"Siri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5634-883X","authenticated-orcid":false,"given":"Howard","family":"Kallender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuTzu","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5021-9412","authenticated-orcid":false,"given":"Diana","family":"Stefani-Hunyady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"3","key":"1043_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","volume":"139","author":"ZC Chiesa Fuxench","year":"2019","unstructured":"Chiesa Fuxench ZC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583\u201390.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1043_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/DER.0000000000000034","volume":"25","author":"JI Silverberg","year":"2014","unstructured":"Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. Dermatitis. 2014;25(3):107\u201314.","journal-title":"Dermatitis"},{"key":"1043_CR3","doi-asserted-by":"crossref","unstructured":"Simpson EL, Eichenfield LF, Alonso-Llamazares J, Draelos ZD, Ferris LK, Forman SB, et al. Roflumilast cream, 0.15%, for atopic dermatitis in adults and children: INTEGUMENT-1 and INTEGUMENT-2 randomized clinical trials. JAMA Dermatol. 2024;160(11):1161\u201370.","DOI":"10.1001\/jamadermatol.2024.3121"},{"key":"1043_CR4","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.6525","volume":"103","author":"D Amiri","year":"2023","unstructured":"Amiri D, Schwarz CW, Gether L, Skov L. Safety and efficacy of topical calcineurin inhibitors in the treatment of facial and genital psoriasis: a systematic review. Acta Derm Venereol. 2023;103:adv00890.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1043_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/bjd.16046","volume":"178","author":"A Ahmed","year":"2018","unstructured":"Ahmed A, Solman L, Williams HC. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal. Br J Dermatol. 2018;178(3):659\u201362.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1043_CR6","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","volume":"75","author":"AS Paller","year":"2016","unstructured":"Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494\u2013503.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1043_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3109\/09546630903401470","volume":"21","author":"SL Chen","year":"2010","unstructured":"Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat. 2010;21(3):144\u201356.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1043_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","volume":"91","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Eichenfield LF, Hebert AA, Simpson EL, Stein Gold L, Bissonnette R, et al. Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024;91(3):457\u201365.","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"1043_CR9","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109\u201317.","journal-title":"Blood"},{"issue":"5","key":"1043_CR10","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","volume":"88","author":"K Papp","year":"2023","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Forman SB, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. J Am Acad Dermatol. 2023;88(5):1008\u201316.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1043_CR11","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1043_CR12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaad.2025.05.1385","volume":"93","author":"LF Eichenfield","year":"2025","unstructured":"Eichenfield LF, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, et al. Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: results from TRuE-AD3, a phase 3, randomized double-blind study. J Am Acad Dermatol. 2025;93(3):689\u201398.","journal-title":"J Am Acad Dermatol"},{"key":"1043_CR13","unstructured":"Eichenfield LF, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM et al. 52-week safety and disease control with ruxolitinib cream in children aged 2\u201311 years with atopic dermatitis: results from the phase 3 TRuE-AD3 study. Presented at 33rd European Academy of Dermatology and Venereology (EADV) Congress; 25\u201328 September, 2024; Amsterdam."},{"key":"1043_CR14","volume-title":"Opzelura\u00ae (ruxolitinib cream). full prescribing information","author":"Incyte Corporation","year":"2025","unstructured":"Incyte Corporation. Opzelura\u00ae (ruxolitinib cream). Full prescribing information. Wilmington (DE). 2025."},{"key":"1043_CR15","unstructured":"Incyte Corporation and Innomar Strategies. Opzelura\u00ae (ruxolitinib cream). Product monograph. Oakville (ON). 2025."},{"issue":"4","key":"1043_CR16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40257-024-00855-2","volume":"25","author":"LF Eichenfield","year":"2024","unstructured":"Eichenfield LF, Simpson EL, Papp K, Szepietowski JC, Blauvelt A, Kircik L, et al. Efficacy, safety, and long-term disease control of ruxolitinib cream among adolescents with atopic dermatitis: pooled results from two randomized phase 3 studies. Am J Clin Dermatol. 2024;25(4):669\u201383.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1043_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40257-022-00690-3","volume":"23","author":"R Bissonnette","year":"2022","unstructured":"Bissonnette R, Call RS, Raoof T, Zhu Z, Yeleswaram S, Gong X, et al. A maximum-use trial of ruxolitinib cream in adolescents and adults with atopic dermatitis. Am J Clin Dermatol. 2022;23(3):355\u201364.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1043_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40257-024-00909-5","volume":"26","author":"L Stein Gold","year":"2025","unstructured":"Stein Gold L, Bissonnette R, Forman S, Zaenglein A, Kuo Y, Angel B, et al. A maximum-use trial of ruxolitinib cream in children aged 2-11 years with moderate to severe atopic dermatitis. Am J Clin Dermatol. 2025;26(2):275\u201389.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1043_CR19","doi-asserted-by":"publisher","first-page":"2310633","DOI":"10.1080\/09546634.2024.2310633","volume":"35","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Bissonnette R, Chiesa Fuxench ZC, Kallender H, Sturm D, Ren H, et al. Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies. J Dermatolog Treat. 2024;35(1):2310633.","journal-title":"J Dermatolog Treat"},{"key":"1043_CR20","doi-asserted-by":"crossref","unstructured":"Carrascosa JM, Prajapati VH, Hong CH, Eleftheriadou V, Tsianakas A, Navarini A, et al. Efficacy and safety of ruxolitinib cream in adults with moderate atopic dermatitis: results from TRuE-AD4, a phase 3b, randomized, double-blind, vehicle-controlled study. Presented at 15th Georg RAJKA International Symposium on Atopic Dermatitis; 24\u201326 October, 2025; Melbourne (VIC).","DOI":"10.1016\/j.jid.2025.09.317"},{"issue":"1","key":"1043_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2480744","volume":"36","author":"ZC Chiesa Fuxench","year":"2025","unstructured":"Chiesa Fuxench ZC, Lai Z, Kuo Y, Nawaz H, Cotliar J. Ruxolitinib cream monotherapy for facial and\/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial. J Dermatolog Treat. 2025;36(1):2480744.","journal-title":"J Dermatolog Treat"},{"key":"1043_CR22","doi-asserted-by":"publisher","unstructured":"Bissonnette R, Saint-Cyr Proulx E, Correa da Rosa J, Estrada Y, Ren H, Nawaz H, et al. Ruxolitinib cream demonstrated rapid and sustained reductions in itch and atopic dermatitis signs that correlated with biomarkers. J Invest Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jid.2025.10.613. (Epub ahead of print).","DOI":"10.1016\/j.jid.2025.10.613"},{"issue":"4","key":"1043_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jaad.2017.06.010","volume":"77","author":"LF Eichenfield","year":"2017","unstructured":"Eichenfield LF, Call RS, Forsha DW, Fowler J Jr, Hebert AA, Spellman M, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1043_CR24","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.jaad.2018.10.054","volume":"80","author":"C Pao-Ling Lin","year":"2019","unstructured":"Pao-Ling Lin C, Gordon S, Her MJ, Rosmarin D. A retrospective study: application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor. J Am Acad Dermatol. 2019;80(5):1451\u20133.","journal-title":"J Am Acad Dermatol"},{"key":"1043_CR25","doi-asserted-by":"crossref","unstructured":"Simpson EL, Eichenfield LF, Papp KA, Forman SB, Hebert AA, Gonzalez ME, et al. Long-term safety and efficacy with roflumilast cream 0.15% in patients aged \u22656 years with atopic dermatitis: a phase 3 open-label extension trial. Dermatitis. 2026;37(1):75\u201383.","DOI":"10.1089\/derm.2024.0418"},{"issue":"1","key":"1043_CR26","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","volume":"89","author":"R Sidbury","year":"2023","unstructured":"Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1-20.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1043_CR27","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jdv.14891","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1043_CR28","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40257-021-00610-x","volume":"22","author":"X Gong","year":"2021","unstructured":"Gong X, Chen X, Kuligowski ME, Liu X, Liu X, Cimino E, et al. Pharmacokinetics of ruxolitinib in patients with atopic dermatitis treated with ruxolitinib cream: data from phase II and III studies. Am J Clin Dermatol. 2021;22(4):555\u201366.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1043_CR29","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s13555-025-01639-0","volume":"16","author":"A Blauvelt","year":"2026","unstructured":"Blauvelt A, Kircik L, Simpson EL, Lio P, Eichenfield LF, Prajapati VH, et al. Ruxolitinib cream as-needed monotherapy demonstrates sustained disease and symptom control in patients with mild to moderate atopic dermatitis: pooled analysis from two phase 3 studies. Dermatol Ther (Heidelb). 2026;16(3):1635\u201346.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01043-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01043-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01043-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:14:19Z","timestamp":1786619659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01043-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1043"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01043-0","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article is revised due to update in copyright line","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Joel C. Joyce has served as a consultant for Incyte Corporation, Pfizer, Regeneron, and Sanofi; a speaker for AbbVie and Sanofi; and an investigator for AbbVie, Aclaris Therapeutics, Amgen, Apogee, CorEvitas, Eli Lilly, Galderma, Incyte Corporation, Janssen, Novartis, Organon, Pfizer, Sanofi, and Verrica. H. Chih-ho Hong has served as a speaker, advisor, consultant, and\/or investigator for AbbVie, Amgen, Arcutis, ASLAN, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cutanea, Dermira, Dermavant, DS Biopharma, Eli Lilly, Evelo Biosciences, Galderma, GlaxoSmithKline, Incyte Corporation, InmageneBio, IQVIA, JAMP, Janssen, LEO Pharma, Medimmune, Merck, Mirimar, Novartis, Organon, Oruka, Pfizer, Regeneron, Roche, Sanofi-Genzyme, Takeda, and UCB. Dareen D. Siri has received research grants from AbbVie, Amgen, Apogee, Biorasi, Dermira (Eli Lilly), Galderma, Incyte Corporation, Pfizer, Q32, Regeneron, Sanofi, and UCB and was a speaker or advisor for AbbVie, Arcutis, Dermavant, Incyte Corporation, Pfizer, Regeneron, and Sanofi. Darryl Toth has served as an investigator for AbbVie, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermavant, Dermira, DS Biopharma, Eli Lilly, Galderma, Incyte Corporation, Janssen, Kymab, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Reistone Biopharma, Sanofi, Sun Pharma, Takeda, UCB, and Zai Lab. Howard Kallender, YuTzu Kuo, and Diana Stefani-Hunyady are employees and shareholders of Incyte Corporation. Kim A. Papp has received honoraria and\/or grants as a consultant, speaker, investigator, or scientific officer from AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health\/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DiCE Pharmaceuticals, DiCE Therapeutics, Eli Lilly and Company, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte Corporation, Janssen, Kymab, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB Pharma, and Zai Lab.","order":1,"name":"Ethics","label":"Conflicts of interest\/competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"These studies were conducted in accordance with Good Clinical Practice guidelines, provisions of the Declaration of Helsinki, and applicable regulations. Study protocols were approved by each site\u2019s institutional review board.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients before any study-related procedures were conducted.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Incyte Corporation is committed to data sharing that advances science and medicine while protecting patient privacy. Qualified external scientific researchers may request anonymized datasets owned by Incyte Corporation for the purpose of conducting legitimate scientific research. Researchers may request anonymized datasets from any interventional study (except phase I studies) for which the product and indication have been approved on or after 1 January, 2020 in at least one major market (e.g., USA, European Union, Japan). Data will be available for request after the primary publication or 2 years after the study has ended. Information on Incyte Corporation\u2019s clinical trial data-sharing policy and instructions for submitting clinical trial data requests are available at:\n                      \n                      .","order":6,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JCJ, HCH, DDS, DT, DS-H, and KAP contributed to data collection and interpretation. HK, YK, and DS-H contributed to data analysis and interpretation. All authors contributed to draft development and critical appraisal of the manuscript. All authors approved the final version of the manuscript for submission and reviewed and approved subsequent revisions leading to the final version.","order":7,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}